Goodman Advisory Group LLC Invests $1.53 Million in IQVIA Holdings Inc. $IQV

Goodman Advisory Group LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 8,997 shares of the medical research company’s stock, valued at approximately $1,534,000.

Other large investors have also recently added to or reduced their stakes in the company. Strive Asset Management LLC acquired a new position in IQVIA during the third quarter worth approximately $17,447,000. Picton Mahoney Asset Management raised its stake in IQVIA by 3,086.9% during the third quarter. Picton Mahoney Asset Management now owns 48,824 shares of the medical research company’s stock worth $9,275,000 after purchasing an additional 47,292 shares during the period. WINTON GROUP Ltd acquired a new position in shares of IQVIA in the 3rd quarter valued at $3,383,000. J. Safra Sarasin Holding AG grew its stake in shares of IQVIA by 174.3% during the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock valued at $2,891,000 after buying an additional 8,151 shares during the period. Finally, Keystone Investors PTE Ltd. grew its stake in shares of IQVIA by 55.1% during the 3rd quarter. Keystone Investors PTE Ltd. now owns 146,228 shares of the medical research company’s stock valued at $27,775,000 after buying an additional 51,958 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on IQV shares. Royal Bank Of Canada began coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. HSBC set a $210.00 price target on IQVIA in a research note on Wednesday, June 3rd. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Stock Performance

NYSE:IQV opened at $191.12 on Friday. The firm’s fifty day simple moving average is $174.43 and its 200 day simple moving average is $190.07. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The firm has a market capitalization of $31.90 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 1.64 and a beta of 1.21.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has authorized a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.